Processa Pharmaceuticals, Inc. (PCSA) is a publicly traded company in the Unknown sector. Across all available filings, 14 corporate insiders have executed 143 transactions totaling $11.3M, demonstrating a bearish sentiment with -$9.7M in net insider flow. The most recent transaction on Jan 1, 2026 involved a transaction of 249 shares valued at $0.
No significant insider buying has been recorded for PCSA in the recent period.
No significant insider selling has been recorded for PCSA in the recent period.
Based on recent SEC filings, insider sentiment for PCSA is bearish with an Insider Alignment Score of 7/100 and a net flow of -$9.7M. Insiders are reducing their positions, though this can be driven by factors unrelated to company outlook.
Insider trading at Processa Pharmaceuticals, Inc. (PCSA) refers to stock transactions made by corporate insiders—executives, directors, and beneficial owners holding more than 10% of the company's shares. These individuals have access to material non-public information and are required by law to report their trades to the SEC within two business days. Currently, 14 insiders are actively trading PCSA stock, having executed 143 transactions in the past 90 days. The most active insider is James E. Besser (Executive), who has made 13 transactions totaling $10.4M.
Get notified when executives and directors at PCSA file new Form 4 transactions
Date | Insider | Title | Type | Shares | Price | Value | Flags |
|---|---|---|---|---|---|---|---|
| Jan 1, 2026 | Bigora Sian | Chief Development Officer | Option Exercise | 249 | $N/A | $0 | |
| Jan 1, 2026 | Bigora Sian | Chief Development Officer | Option Exercise | 249 | $N/A | $0 | |
| Jan 1, 2026 | Guy Wendy | Chief Administrative Officer | Option Exercise | 193 | $N/A | $0 | |
| Jan 1, 2026 | Guy Wendy | Chief Administrative Officer | Option Exercise | 193 | $N/A | $0 | |
| Jan 1, 2026 | Lin Patrick | Chief Business - Strategy Off | Option Exercise | 193 | $N/A | $0 | |
| Jan 1, 2026 | Lin Patrick | Chief Business - Strategy Off | Option Exercise | 193 | $N/A | $0 | |
| Jan 1, 2026 | Young David | Executive | Option Exercise | 49 | $N/A | $0 | |
| Jan 1, 2026 | Young David | Executive | Option Exercise | 49 | $N/A | $0 | |
| Jul 10, 2024 | Young David | Executive | Option Exercise | 644 | $N/A | $0 | |
| Jul 10, 2024 | Young David | Executive | Payment | 282 | $1.71 | $482 | |
| Jul 10, 2024 | Guy Wendy | Executive | Option Exercise | 644 | $N/A | $0 | |
| Jul 10, 2024 | Guy Wendy | Executive | Payment | 220 | $1.71 | $376 | |
| Jul 10, 2024 | Lin Patrick | Executive | Option Exercise | 644 | $N/A | $0 | |
| Jul 10, 2024 | Lin Patrick | Executive | Payment | 271 | $1.71 | $463 | |
| Jul 10, 2024 | H. Stanker James | Executive | Payment | 282 | $1.71 | $482 |
| TYPE | COUNT | VALUE | % |
|---|---|---|---|
Sale(S) | 17 | $10.5M | 91.0% |
Purchase(P) | 27 | $766.0K | 6.6% |
Award(A) | 33 | $209.0K | 1.8% |
Payment(F) | 22 | $59.0K | 0.5% |
Exercise(M) | 40 | $0 | 0.0% |
Other(J) | 1 | $0 | 0.0% |
Gift(G) | 3 | $0 | 0.0% |
Insider selling pressure at Processa Pharmaceuticals, Inc. has increased, with 14 insiders executing 143 transactions across all time. Total sales of $10.5M significantly outpace purchases of $766.0K, resulting in a net outflow of $9.7M. This selling activity appears largely discretionary, which may warrant closer attention from investors.